Market revenue in 2022 | USD 486.2 million |
Market revenue in 2030 | USD 899.6 million |
Growth rate | 8% (CAGR from 2022 to 2030) |
Largest segment | Estrogen and progesterone replacement therapy |
Fastest growing segment | Parathyroid Hormone replacement |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Estrogen and Progesterone Replacement Therapy, HGH replacement therapy, Thryoid hormone replacement therapy, Testosterone Replacement Therapy, Parathyroid Hormone replacement |
Key market players worldwide | Eli Lilly and Co, Bayer AG, Hisamitsu Pharmaceutical Co Inc, Pfizer Inc, Merck & Co Inc, Viatris Inc, Novo Nordisk A/S ADR, AbbVie Inc, Roche Holding AG ADR, Ascend Wellness Holdings Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hormone replacement therapy market will help companies and investors design strategic landscapes.
Estrogen and progesterone replacement therapy was the largest segment with a revenue share of 53.39% in 2022. Horizon Databook has segmented the South Korea hormone replacement therapy market based on estrogen and progesterone replacement therapy, hgh replacement therapy, thryoid hormone replacement therapy, testosterone replacement therapy, parathyroid hormone replacement covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing prevalence of hypothyroidism and other target diseases is projected to drive market growth over the forecast period. According to an article published by Medicine, (May 2020), the prevalence of hypothyroidism was found to be 4% to 15% of the total global population and in South Korea, hypothyroidism affected around 14% of the whole population.
Currently, Levothyroxine is the standard and basic method for treatment of these patients. The precise dose is given as per the physician’s prescription for avoiding side effects such as vomiting, nausea, headache, and muscle cramps.
For instance, in April 2022, LG Chem received approval from the Ministry of Food and Drug Safety for its Eutropin S Pen for the treatment of pediatric growth failure. It consists of somatropin, a recombinant human growth hormone injection, and has a shelf life of 24 months.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea hormone replacement therapy market , including forecasts for subscribers. This country databook contains high-level insights into South Korea hormone replacement therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account